Category list : Antineoplastic agents
Sort by: Newest first Oldest first A-Z Z-A
-
Wales will not have a Cancer Drugs Fund, health minister says Subscription
Wales will not have a Cancer Drugs Fund, despite a 98,000-signature petition calling for equity of access to cancer drugs for patients in England and Wales being handed to the Welsh Assembly on 5 November 2014.
-
Adding bevacizumab to triple therapy improves outcome in colorectal cancer Subscription
Patient outcome is improved when bevacizumab is given with a triple- rather than a two-drug combination in metastatic colorectal cancer.
-
Green light for first treatment to target ovarian cancer with BRCA mutation Subscription
The European Medicines Agency has recommended that Lynparza (olaparib) be approved to combat a type of ovarian cancer for which there are limited treatment options.
-
Scientific advances are not translating into new cancer drugs, expert warns Subscription
The global system for discovering new cancer drugs is failing to turn scientific advances into innovative new medicines, Paul Workman, interim chief executive of The Institute of Cancer Research in London has warned.
-
Treatment tested for patients with visceral leishmaniasis and HIV in Africa Subscription
The efficacy and safety of amphotericin plus miltefosine to treat visceral leishmaniasis patients with HIV will be examined in a Phase III randomized clinical trial in Ethiopia.
-
Cancer drugs approved faster in the United States than in Europe or Canada Subscription
Regulatory agencies in the United States take less time to approve new cancer drugs than those in Europe or Canada, according to new research.
-
New melanoma treatment approved by NICE Subscription
The National Institute for Health and care Excellence has issued draft guidance recommending that dabrafenib should be available on the NHS for the treatment of melanoma that has spread or can’t be completely removed by surgery in patients with a BRAF gene mutation.
-
Promising results for lenalidomide plus dexamethasone in myeloma Subscription
A trial involving more than 1,600 patients with multiple myeloma showed improvement in progression-free survival with a new combination therapy.
-
Rare blood cancer treatments recommended for approval by the EMA
The European Medicines Agency has approved two new medicines, ibrutinib (Janssen-Cilag’s Imbruvica) and idelalisib (Gilead Science’s Zydelig), for adult patients with rare blood cancers.
-
Exposure to light at night may reduce effectiveness of breast cancer drug tamoxifen
Keeping the lights on during the night may cause breast cancer patients to become resistant to a commonly-prescribed treatment.
Show 10 per page20 per page50 per page
